SCHEMBL8199540

SCHEMBL8199540

O=C1c2cccc(O)c2C(=O)c2c(O)cc(O)cc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.74
MAPT P10636 5/20 0.74
TDP1 Q9NUW8 5/20 0.74
TSHR P16473 4/20 0.74
MAOA P21397 4/20 0.74
MAPK1 P28482 4/20 0.74
LMNA P02545 3/20 0.74
ALOX15 P16050 3/20 0.74
MAOB P27338 3/20 0.74
HSD17B10 Q99714 3/20 0.74
HPGD P15428 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
HTT P42858 1/20 0.74
BCL2 P10415 1/20 0.73
MCL1 Q07820 1/20 0.73
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
CYP3A4 P08684 4/20 0.70
ELANE P08246 4/20 0.70
RECQL P46063 3/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29928697 1.00 ALDH1A1 (0.74) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL29406720 0.94 BCL2 (0.76) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL3190101 0.94 BCL2 (0.76) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL16432715 0.86 ELANE (0.67) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL29596527 0.86 ELANE (0.67) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL29596416 0.86 ELANE (0.67) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL30544826 0.86 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL29356886 0.86 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL83688 0.86 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL29390162 0.86 ESR1 (0.77) ALDH1A1MAPTTDP1TSHRMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119424397-A Application of aloe-emodin in preparing medicine for treating pulmonary arterial hypertension 大连医科大学 2025-02-14 CN claimed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
CN-119424397-A Application of aloe-emodin in preparing medicine for treating pulmonary arterial hypertension 大连医科大学 2025-02-14 CN disclosed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
CN-118032745-A Rhubarb vegetable dye and identification method of dyed fabric thereof 上海中纺联和生态科技有限公司 2024-05-14 CN disclosed
CN-107847466-B Formulations and methods for modulating wound healing 贝欧曼蒂克丝公司 2024-02-06 CN disclosed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20210380518-A1 COMPOUNDS AND METHODS OF USING COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASES Shekdar, Kambiz (US) 2021-12-09 US disclosed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-20160296477-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2016-10-13 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
CN-105012412-A Medicinal composition for treating kidney diseases and pharmaceutical use of medicinal composition XI AN SHIJISHENGKANG PHARMACEUTICAL INDUSTRY CO LTD 2015-11-04 CN disclosed
CN-104997855-A Pharmaceutical composition containing total anthraquinone in rheum and total salvianolic acids and pharmaceutical application thereof XI AN SHIJISHENGKANG PHARMACEUTICAL INDUSTRY CO LTD 2015-10-28 CN disclosed
US-6150414-A INHIBITING A VIRUS CAUSING INFECTION (SUCH AS HIV) BY ADMINISTERING THE COMPOUND 1,3,4,6-TETRAHYDROXY-7,16-DIOXO-7,16-DIHYDRO-DIBENZO(A,O)PERYLENE NEW YORK UNIVERSITY (US) 2000-11-21 US disclosed
EP-0426785-B1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS UNIV NEW YORK (US) 1998-09-02 EP disclosed
EP-0426785-A4 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS 1991-11-13 EP disclosed
EP-0426785-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS NEW YORK UNIVERSITY (US) 1991-05-15 EP disclosed
WO-1990010438-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS NEW YORK UNIVERSITY (US) 1990-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380518-A1 COMPOUNDS AND METHODS OF USING COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASES ACE2, ACE, CFTR ALDH1A1 2907/4885MAPT 2426/4885TDP1 4341/4885
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB ALDH1A1 2877/4885MAPT 3534/4885TDP1 1811/4885
US-20160296477-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB ALDH1A1 2491/4885MAPT 3766/4885TDP1 1661/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 ALDH1A1 2362/4885MAPT 3091/4885TDP1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.